人工肝联合恩替卡韦治疗慢加亚急性肝衰竭的临床效果

Abstract
Figure/Table
References (16)
Related Citation (11)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of artificial liver combined with Entecavir in the treatment of chronic subacute liver failure.Methods A total of 70 patients with chronic subacute early liver failure admitted to Ganzhou Fifth People′s Hospital from October 2017 to February 2019 were selected as the research subjects,they were divided into the control group (35 cases) and the experimental group (35 cases) according to the odd-even numbers.The control group was treated with conventional medical treatment and Entecavir,while the experimental group was treated with artificial liver combined with Entecavir on the basis of conventional medical treatment.The liver function index,treatment effect,anxiety and depression status and the ability of daily living were compared between the two groups.Results The prealbumin (PA) and cholinesterase (CHE) of the experimental group were higher than those of the control group,and the total serum bilirubin (TBil) was lower than that of the control group,the differences were statistically significant (P＜0.05).The total effective rate of the experimental group was higher than that of the control group,the difference was statistically significant (P＜0.05).The self-rating anxiety scale (SAS) and self-rating depression scale(SDS) scores in the experimental group were lower than those in the control group,and the activities of daily living scale (Barthel) score in the experimental group was higher than that in the control group,the differences were statistically significant (P＜0.05).Conclusion For chronic and subacute liver failure (early stage) disease,the clinical use of artificial liver combined with entecavir is effective and worthy of clinical promotion.

Key words： Artificial liver Entecavir Chronic subacute liver failure Early disease

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LUO Ying-mi
	ZENG Yi-jun BAO
	Long-yuan LIU
	Chang-hong

Cite this article:

LUO Ying-mi,ZENG Yi-jun BAO,Long-yuan LIU, et al. Clinical effect of artificial liver combined with Entecavir in the treatment of chronic subacute liver failure[J]. 中国当代医药, 2021, 28(7): 43-45.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I7/43

[1]	严丽军，徐立新.人工肝选择性血浆置换治疗慢加亚急性肝衰竭及费效比分析[J].肝脏，2018，23（4）：361-362.
[2]	卢玲玲，张会，耿爱文，等.以亚急性肝衰竭为首发表现的自身免疫性肝炎1例报告[J].临床肝胆病杂志，2019，35（10）：2292-2294.
[3]	余婷婷，张伦理，葛善飞，等.抗真菌药物在采用糖皮质激素治疗慢加急性（亚急性）肝衰竭患者中的预防作用[J].中华传染病杂志，2019，37（9）：534-539.
[4]	李清奇，郭婷，张丽丽，等.人工肝血浆置换术治疗肝衰竭的临床效果[J].中国当代医药，2020，27（17）：40-42.
[5]	李晨，游绍莉，辛绍杰.HBV 相关慢加急性肝衰竭前期概念及诊疗新进展[J].实用肝脏病杂志，2015，10（1）：105-108.
[6]	郭倩，崔雨，刘青.恩替卡韦与替诺福韦在慢乙肝相关性肝衰竭预后的效果观察[J].临床研究，2020，28（1）：56-57.
[7]	吴学伟.1例重症亚急性肝衰竭患者人工肝血浆置换术的护理[J].心理医生，2018，24（27）：187-188.
[8]	雷青，孟忠吉.慢加急性肝衰竭的研究进展[J].中国医药导报，2016，13（14）：45-48.
[9]	曾庆磊，吕君，付艳玲，等.慢加急性肝衰竭的定义与治疗[J].肝脏，2016，21（1）：66-67.
[10]	朱其荣，李玲，梅小平.恩替卡韦分散片治疗慢性乙型病毒性肝炎慢加急性肝衰竭的近期疗效[J].广东医学，2016，37（8）：1218-1220.
[11]	李保欣，张岁，段卫，等.两种恩替卡韦制剂治疗慢加急性乙型肝炎肝衰竭患者疗效对比研究[J].实用肝脏病杂志，2017，20（003）：298-301.
[12]	梁桂才，黄献球.拉米夫定与恩替卡韦治疗慢性乙型肝炎慢加急性肝功能衰竭的对比研究[J].成都医学院学报，2016，44（1）：64-67.
[13]	戴金津，朱传武，蔡伟，等.恩替卡韦早期抗病毒治疗对乙型肝炎相关慢加急性肝衰竭转归的影响[J].肝脏，2018，23（10）：27-31.
[14]	刘春涛，武瑞，俞海燕，等.双重血浆分子吸附模式人工肝治疗乙肝相关慢加急性肝衰竭的疗效观察[J].浙江医学，2019，41（2）：24-26.
[15]	单大军，吕慧敏.恩替卡韦治疗乙肝病毒所致肝衰竭的临床观察[J].中国保健营养，2019，29（3）：35，34.
[16]	王金明，洪伟勇，申慧玲，等.1例布洛芬致亚急性肝衰竭的病例分析与药学监护[J].临床药物治疗杂志，2019，17（7）：85-88.